Please assess the completion status of the following clinical trial:

Trial Title: DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥20 years old in Japan, ≥18 years old in other countries~* Pathologically documented unresectable and/or metastatic non-squamous NSCLC~* Has relapsed from or is refractory to standard treatment or for which no standard treatment is available~* For Cohort 1 and Cohort 1a: HER2-overexpression (IHC 2+ or 3+) status must be assessed and confirmed by Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory or equivalent, from an archival tumor tissue sample~* For Cohort 2 only: Participant has any known documented activating HER2 mutation from an archival tumor tissue sample analyzed by CLIA laboratory or equivalent. Note: HER2 mutation documented only from a liquid biopsy sample cannot be used for enrollment.~* Presence of at least 1 measurable lesion assessed by the investigator and based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1~* Is willing and able to provide an adequate archival tumor tissue sample~* Is willing to undergo a tissue biopsy, after the completion of the most recent treatment regimen~* Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1~Exclusion Criteria:~* Had been previously treated with HER2-targeted therapies, except for pan-HER class tyrosine kinase inhibitors~* For Cohort 1 and Cohort 1a: Has known HER2 mutation~* Has a medical history of myocardial infarction, symptomatic congestive heart failure (CHF) (NYHA classes II-IV), unstable angina or serious cardiac arrhythmia~* Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, or current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out due to imaging at screening~* Has a QT interval corrected by Fridericia's formula (QTcF) prolongation to \> 450 millisecond (ms) in males and \> 470 ms in females~* Has a medical history of clinically significant lung disease~* Is suspected to have certain other protocol-defined diseases based on imaging at screening period~* Has history of any disease, metastatic condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:~  1. safety or well-being of the participant or offspring~ 2. safety of study staff~ 3. analysis of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: HER2 Overexpressing (Type: EXPERIMENTAL): Participants with HER2-overexpressing(immunohistochemistry \[IHC\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
- Cohort 1a: HER2 Overexpressing (Type: EXPERIMENTAL): Participants with HER2-overexpressing (immunohistochemistry \[IHC\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).
- Cohort 2: HER2 Mutated (Type: EXPERIMENTAL): Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete